Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1995-12-14
1999-09-21
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241841, 4241851, 4241901, 4241921, 4241931, 4241941, 42419711, 4242001, 4242341, 424823, 424824, 424825, 424826, 424828, 424829, 435 41, 435 42, 435 691, 4351721, 4351722, 4351723, 435243, 4352521, 4352523, 43525234, 4353201, A61K 39108
Patent
active
059550902
ABSTRACT:
The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.
REFERENCES:
Hughes et al., "Synthetic Peptides Representing Epitopes of Outer Membrane Protein F of Pseudomonas Aeruginosa That Elicit Antibodies Reactive with Whole Cells of Heterologous Immunotype Strains of P. Aeruginosa", Infect. Immun., 60(9):3497-3503 (1992).
Finke et al., "Protection Against Experimental Pseudomonas Aeruginosa Infection by Recombinant P. Aeruginosa Lipoprotein I Expressed in Escherichia Coli", Infect. Immun., 58(7):2241-2244 (1990).
Duchene et al., "Sequence and Transcriptional Start Site of the Pseudomonas Aeruginosa Outer Membrane Porin F Gene", J. Bacteriol., 170(1)155-162 (1988).
Duchene et al., "Pseudomonas Aeruginosa Outer Membrane Liproprotein I Gene: Molecular Cloning, Sequence, and Expression in Escherichia Coli", J. Bacteriol., 171(8):4130-4137 (1989).
Roussilhon et al., "Responses of T Cells From Sensitized Donors to Recombinant and Synthetic Peptides Corresponding to Sequences of the Plasmodium Falciparum SERP Antigen", Immunol. Lett., 25:149-154 (1990).
Johnson et al., "Improved Technique Utilizing Nonfat Dry Milk for Analysis of Proteins and Nucleic Acids Transferred to Nitrocellulose", Gene Anal. Techn., 1:3-8 (1984).
Schorr et al., "Surface Expression of Malarial Antigens in Salmonella Typhimurium: Induction of Serum Antibody Response Upon Oral Vaccination of Mice", Vaccine, 9:675-681 (1991).
Horton et al., "Engineering Hybrid Genes Without The Use of Restriction Enzymes: Gene Splicing by Overlap Extension", Gene, 77:61-68 (1989).
Baldari et al., "A Novel Leader Peptide Which Allows Efficient Secretion of a Fragment of Human Interleukin 1.beta. in Saccharomyces Cerevisiae", EMBO. J., 6(1):229-234 (1987).
Finke et al., "Protection of Immunosuppressed Mice Against Infection With Pseudomonas Aeruginosa by Recombinant P. Aeruginosa Lipoprotein I and Lipoprotein I-Specific Monoclonal Antibodies", Infect. Immun., 59(4):1251-1254 (1991).
Finnen et al., "Analysis of the Pseudomonas aeruginosa Major Outer Membrane Protein OprF by Use on Truncated OprF Derivatives and Monoclonal Antibodies", J. Bacteriol, 174(15):4977-4985 (1992).
Von Specht et al., "Outer Membrane Proteins of Pseudomonas aerunginosa as Vaccine Candidates", Behring Inst. Mitt., 95:85-96 (1994).
v. Specht, B.-U., et al., "Outer Membrane Proteins of Pseudomonas Aeruginosa as Vaccine Candidates," Behring Inst. Mitt., vol. 95, pp. 85-96.
Finnen, Renee L., et al., "Analysis of the Pseudomonas aeruginosa Major Outer Membrane Protein OprF by Use of Truncated OprF Derivatives and Monoclonal Antibodies," J. Bacteriol. 174(15):4977-4985 (Aug. 1992).
Finke, M. et al., "Protection of Immunosuppressed Mice against Infection with Pseudomonas aeruginosa by a Recombinant P. aeruginosa Lipoprotein I and Lipoprotein I-Specific Monoclonal Antibodies," Infect. and Immun. 59(4):1251-54 (Apr. 1991).
Hughes, Eileen E., et al., "Synthetic Peptides Representing Epitopes of Outer Membrane Protein F of Pseudomonas aeruginosa That Elicit Antibodies Reactive with Whole Cells of Heterologous Immunotype Strains of P. aeruginosa," Infect. and Immun. 60(9):3497-3503 (Sep. 1992).
Broker Michael
Domdey Horst
Hungerer Klaus-Dieter
Knapp Bernhard
von Specht Bernd-Ulrich
Blackburn Robert P
Chiron Behring GmbH & Co.
Harbin Alisa A.
Housel James C.
Nguyen Bao-Thuy L.
LandOfFree
Immunogenic hybrid protein OprF-OprI derived from Pseudomonas ae does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic hybrid protein OprF-OprI derived from Pseudomonas ae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic hybrid protein OprF-OprI derived from Pseudomonas ae will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-77686